These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1763190)

  • 21. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder.
    Broocks A; Bandelow B; George A; Jestrabeck C; Opitz M; Bartmann U; Gleiter CH; Meineke I; Roed IS; Rüther E; Hajak G
    Int Clin Psychopharmacol; 2000 May; 15(3):153-61. PubMed ID: 10870873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
    Broocks A; Meyer T; Opitz M; Bartmann U; Hillmer-Vogel U; George A; Pekrun G; Wedekind D; Rüther E; Bandelow B
    Eur Neuropsychopharmacol; 2003 May; 13(3):153-64. PubMed ID: 12729940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?].
    Davids E; Lesch KP
    Fortschr Neurol Psychiatr; 1996 Nov; 64(11):460-72. PubMed ID: 9064274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin receptor subtypes: implications for psychopharmacology.
    Cowen PJ
    Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety.
    Murphy DL; Pigott TA
    J Clin Psychiatry; 1990 Apr; 51 Suppl():53-8; discussion 59-60. PubMed ID: 2139026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.
    Millan MJ; Rivet JM; Canton H; Le Marouille-Girardon S; Gobert A
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1364-76. PubMed ID: 8450471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans.
    Lesch KP; Poten B; Söhnle K; Schulte HM
    Eur J Clin Pharmacol; 1990; 39(1):17-9. PubMed ID: 1980461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration.
    Gilbert F; Brazell C; Tricklebank MD; Stahl SM
    Eur J Pharmacol; 1988 Mar; 147(3):431-9. PubMed ID: 2897920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrinological responses to 5-HT.
    Cowen PJ; Anderson IM; Gartside SE
    Ann N Y Acad Sci; 1990; 600():250-7; discussion 257-9. PubMed ID: 2252313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin: a common neurobiologic substrate in anxiety and depression.
    Eison MS
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):26S-30S. PubMed ID: 2198299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the neuroendocrine role of serotonin.
    Jørgensen HS
    Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine effects of azapirones.
    Cowen PJ; Anderson IM; Grahame-Smith DG
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):21S-25S. PubMed ID: 1973937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
    Robinson DS; Rickels K; Feighner J; Fabre LF; Gammans RE; Shrotriya RC; Alms DR; Andary JJ; Messina ME
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):67S-76S. PubMed ID: 2198303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls.
    Shiah IS; Yatham LN; Lam RW; Tam EM; Zis AP
    Neuropsychobiology; 1998; 38(1):6-12. PubMed ID: 9701716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT1A receptor sensitivity in depression and anxiety disorders: molecular mechanisms of neuroadaption.
    Lesch KP; Aulakh CS; Murphy DL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():208A-209A. PubMed ID: 1498813
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of acute and repeated versus sustained administration of the 5-HT1A receptor agonist ipsapirone: electrophysiological studies in the rat hippocampus and dorsal raphe.
    Dong J; de Montigny C; Blier P
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):303-11. PubMed ID: 9303566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635.
    Cryan JF; Kelliher P; Kelly JP; Leonard BE
    J Psychopharmacol; 1999; 13(3):278-83. PubMed ID: 10512084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effect of serotonin 5-HT(1A) receptor antagonists on the secretion of corticotropin and prolactin.
    Jørgensen H; Kjaer A; Warberg J; Knigge U
    Neuroendocrinology; 2001 May; 73(5):322-33. PubMed ID: 11399905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.